SLC22A1 and Parkinsonism: In a population-based cohort study, the polymorphism c.1386A>C (rs622342), localized in a non-coding region of the SLC22A1 gene, was associated with higher prescribed doses of anti-Parkinson drugs and a shorter survival after start of levodopa therapy [64].